233 related articles for article (PubMed ID: 22914778)
1. Melanocortin antagonism ameliorates muscle wasting and inflammation in chronic kidney disease.
Cheung WW; Mak RH
Am J Physiol Renal Physiol; 2012 Nov; 303(9):F1315-24. PubMed ID: 22914778
[TBL] [Abstract][Full Text] [Related]
2. A balancing act: protein-energy wasting in chronic kidney disease.
Wing MR; Raj DS
Am J Physiol Renal Physiol; 2012 Dec; 303(12):F1608-9. PubMed ID: 23019231
[No Abstract] [Full Text] [Related]
3. Modulation of melanocortin signaling ameliorates uremic cachexia.
Cheung WW; Rosengren S; Boyle DL; Mak RH
Kidney Int; 2008 Jul; 74(2):180-6. PubMed ID: 18432186
[TBL] [Abstract][Full Text] [Related]
4. Genetic and pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in rodent models of heart failure.
Scarlett JM; Bowe DD; Zhu X; Batra AK; Grant WF; Marks DL
J Endocrinol; 2010 Jul; 206(1):121-30. PubMed ID: 20371568
[TBL] [Abstract][Full Text] [Related]
5. A pegylated leptin antagonist ameliorates CKD-associated cachexia in mice.
Cheung WW; Ding W; Gunta SS; Gu Y; Tabakman R; Klapper LN; Gertler A; Mak RH
J Am Soc Nephrol; 2014 Jan; 25(1):119-28. PubMed ID: 24115476
[TBL] [Abstract][Full Text] [Related]
6. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice.
Joppa MA; Gogas KR; Foster AC; Markison S
Peptides; 2007 Mar; 28(3):636-42. PubMed ID: 17204351
[TBL] [Abstract][Full Text] [Related]
7. The role of IL-1 in adipose browning and muscle wasting in CKD-associated cachexia.
Cheung WW; Zheng R; Hao S; Wang Z; Gonzalez A; Zhou P; Hoffman HM; Mak RH
Sci Rep; 2021 Jul; 11(1):15141. PubMed ID: 34302016
[TBL] [Abstract][Full Text] [Related]
8. Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease-associated cachexia.
Zhu X; Callahan MF; Gruber KA; Szumowski M; Marks DL
J Clin Invest; 2020 Sep; 130(9):4921-4934. PubMed ID: 32544087
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D ameliorates adipose browning in chronic kidney disease cachexia.
Cheung WW; Ding W; Hoffman HM; Wang Z; Hao S; Zheng R; Gonzalez A; Zhan JY; Zhou P; Li S; Esparza MC; Lieber RL; Mak RH
Sci Rep; 2020 Aug; 10(1):14175. PubMed ID: 32843714
[TBL] [Abstract][Full Text] [Related]
10. A Leptin Receptor Antagonist Attenuates Adipose Tissue Browning and Muscle Wasting in Infantile Nephropathic Cystinosis-Associated Cachexia.
Gonzalez A; Cheung WW; Perens EA; Oliveira EA; Gertler A; Mak RH
Cells; 2021 Jul; 10(8):. PubMed ID: 34440723
[TBL] [Abstract][Full Text] [Related]
11. Update on melanocortin interventions for cachexia: progress toward clinical application.
DeBoer MD
Nutrition; 2010 Feb; 26(2):146-51. PubMed ID: 20004082
[TBL] [Abstract][Full Text] [Related]
12. Beyond nutrition: neuropeptide signaling and muscle mass maintenance in chronic kidney disease.
Roberts TK; Bailey JL
Kidney Int; 2008 Jul; 74(2):143-5. PubMed ID: 18591943
[TBL] [Abstract][Full Text] [Related]
13. Growth Hormone Improves Adipose Tissue Browning and Muscle Wasting in Mice with Chronic Kidney Disease-Associated Cachexia.
Mak RH; Gunta S; Oliveira EA; Cheung WW
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499637
[TBL] [Abstract][Full Text] [Related]
14. Differential Effects of 25-Hydroxyvitamin D
Mak RH; Querfeld U; Gonzalez A; Gunta S; Cheung WW
Cells; 2021 Dec; 10(12):. PubMed ID: 34943890
[TBL] [Abstract][Full Text] [Related]
15. Long-noncoding RNA Atrolnc-1 promotes muscle wasting in mice with chronic kidney disease.
Sun L; Si M; Liu X; Choi JM; Wang Y; Thomas SS; Peng H; Hu Z
J Cachexia Sarcopenia Muscle; 2018 Oct; 9(5):962-974. PubMed ID: 30043444
[TBL] [Abstract][Full Text] [Related]
16. Signal regulatory protein alpha initiates cachexia through muscle to adipose tissue crosstalk.
Wu J; Dong J; Verzola D; Hruska K; Garibotto G; Hu Z; Mitch WE; Thomas SS
J Cachexia Sarcopenia Muscle; 2019 Dec; 10(6):1210-1227. PubMed ID: 31507080
[TBL] [Abstract][Full Text] [Related]
17. Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs.
Solagna F; Tezze C; Lindenmeyer MT; Lu S; Wu G; Liu S; Zhao Y; Mitchell R; Meyer C; Omairi S; Kilic T; Paolini A; Ritvos O; Pasternack A; Matsakas A; Kylies D; Wiesch JSZ; Turner JE; Wanner N; Nair V; Eichinger F; Menon R; Martin IV; Klinkhammer BM; Hoxha E; Cohen CD; Tharaux PL; Boor P; Ostendorf T; Kretzler M; Sandri M; Kretz O; Puelles VG; Patel K; Huber TB
J Clin Invest; 2021 Jun; 131(11):. PubMed ID: 34060483
[TBL] [Abstract][Full Text] [Related]
18. Leptin and inflammation-associated cachexia in chronic kidney disease.
Mak RH; Cheung W; Cone RD; Marks DL
Kidney Int; 2006 Mar; 69(5):794-7. PubMed ID: 16518340
[TBL] [Abstract][Full Text] [Related]
19. Control of food intake and muscle wasting in cachexia.
Amitani M; Asakawa A; Amitani H; Inui A
Int J Biochem Cell Biol; 2013 Oct; 45(10):2179-85. PubMed ID: 23911307
[TBL] [Abstract][Full Text] [Related]
20. Muscle wasting in chronic kidney disease.
Oliveira EA; Cheung WW; Toma KG; Mak RH
Pediatr Nephrol; 2018 May; 33(5):789-798. PubMed ID: 28508131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
